#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Kaposi's sarcoma Congenital generalised lipodystrophy Palmar-plantar erythrodysaesthesia syndrome Transferrin decreased Cerebral arteriovenous malformation haemorrhagic Myotonic dystrophy Nephropathy Chronic graft versus host disease in intestine Congenital myopathy Biliary neoplasm Pemphigoid Adenocarcinoma gastric Phenylketonuria Malignant central nervous system neoplasm Essential thrombocythaemia More trials…

    Learn about Rare Diseases

    Atypical haemolytic uraemic syndrome – Trials in Disease Biotinidase deficiency – Treatment MELAS syndrome – Life with Disease Fragile X syndrome – Diagnostics Mucous membrane pemphigoid – Life with Disease Leiomyosarcoma metastatic – Diagnostics Osteosarcoma – Trials in Disease Toxic epidermal necrolysis Alexander disease – Treatment Ewing’s sarcoma recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Voriconazole Tocilizumab Amantadine Hemisulfate XELAFASLATIDE Ifinatamab Deruxtecan ENSIFENTRINE TAGRAXOFUSP Cabergoline Mps-200 Golcadomide RIKKUNSHITO Delafloxacin Dnth103 Epinephrine Bitartrate Tigulixostat Beclometasone Dipropionate Icatibant Bortezomib Bi-1808 Inavolisib More therapies…

    Learn about Your Condition

    Radicular pain Hyponatraemia Inborn error of metabolism Polycythaemia vera Arteriosclerosis Cold urticaria Genital infection female Hypoxia Pulmonary sarcoidosis Haemorrhoids Necrotising myositis Trigeminal neuralgia Renal injury Renal cancer metastatic Psychological trauma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic myeloid leukaemia

  • Study on the Effectiveness and Safety of Ropeginterferon and Bosutinib for Patients with Chronic Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Ropeginterferon Alfa-2B
    • Bosutinib
    Denmark Finland Norway Sweden

  • Study of ponatinib and azacitidine combination treatment in patients with accelerated phase or blast crisis chronic myelogenous leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Ponatinib
    France

  • Study on Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: Comparing Dasatinib, Imatinib, Nilotinib, and Bosutinib Strategies

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Bosutinib
    • Imatinib
    • Dasatinib
    France

  • Study of treatment discontinuation with nilotinib and asciminib in adults with chronic myeloid leukemia to achieve treatment-free remission

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Asciminib Hydrochloride
    • Nilotinib
    Italy

  • Study on the Effectiveness of Asciminib and Imatinib for Patients with Chronic Myelogenous Leukemia Not Responding to Imatinib

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Asciminib Hydrochloride
    • Imatinib
    • Nilotinib
    Austria Czechia France Italy Spain

  • Study of dose reduction strategy for tyrosine kinase inhibitors (imatinib, ponatinib, bosutinib, nilotinib, dasatinib) in patients with chronic myeloid leukemia

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bosutinib
    • Dasatinib
    • Imatinib Mesilate
    The Netherlands
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!